Rheumatology International

, Volume 35, Issue 11, pp 1781–1789 | Cite as

Polymyalgia rheumatica: strategies for efficient practice and quality assurance

  • Michael Schirmer
  • Christian Dejaco
  • Bhaskar Dasgupta
  • Eric L. MattesonEmail author
Review Article - Review Health Services


Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in persons over the age of 50 years. There are many diseases which mimic PMR, for which reason a careful diagnostic approach is required. While it is thought to be exquisitely responsive to glucocorticosteroid therapy, many patients respond incompletely and/or develop serious side effects over the protracted disease course. Improved methods for classification and disease assessment together with standardized treatment approaches and outcome assessments can serve to improve the care of patients with this disease.


Polymyalgia rheumatica Quality measures Diagnosis Classification criteria Treatment Outcome 


  1. 1.
    Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, National Deyo RA, Workgroup Arthritis Data et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58(1):26–35PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Doran MF, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE (2002) Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 29:1694–1697PubMedGoogle Scholar
  3. 3.
    Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ (1999) Corticosteroid requirements in polymyalgia rheumatica. Arch Int Med 159(6):577–584CrossRefGoogle Scholar
  4. 4.
    Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA, Schirmer M, Salvarani C et al (2012) Patient reported outcomes in polymyalgia rheumatica. J Rheumatol 39(4):795–803CrossRefPubMedGoogle Scholar
  5. 5.
    Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B et al (2007) Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 57(5):803–809CrossRefPubMedGoogle Scholar
  6. 6.
    Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C et al (2012) European League Against Rheumatism/American College of Rheumatology provisional classification criteria for polymyalgia rheumatica. Ann Rheum Dis 71:484–492PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Maradit-Kremers H, Dasgupta B, Matteson EL (2009) Polymyalgia rheumatica. In: Preedy VR, Watson RR (eds) Handbook of disease burdens and quality of life measures. Springer, Berlin, pp 3996–4012Google Scholar
  8. 8.
    BSR and BHPR Standards, Guidelines and Audit Working Group, Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J et al (2010) BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49(1):186–190CrossRefGoogle Scholar
  9. 9.
    Dasgupta B, Matteson EL, Maradit-Kremers H (2007) Management guidelines and outcome measures in polymyalgia rheumatica (PMR). Clin Exp Rheumatol 25(suppl 47):S130–S136Google Scholar
  10. 10.
    ACR/EULAR PMR Guidelines Development Group, Dejaco C, Singh Y, Perel P, Hutchings A, Matteson EL, Dasgupta B (2014) Current evidence for therapeutic interventions in polymyalgia rheumatica (PMR): a systematic literature review informing the ACR/EULAR recommendations for the management of PMR. Ann Rheum Dis 73(suppl2):552Google Scholar
  11. 11.
    Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347(4):261–271CrossRefPubMedGoogle Scholar
  12. 12.
    Weyand CM, Goronzy JJ (2014) Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 371(1):50–57PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG (2000) The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 27:2179–2184PubMedGoogle Scholar
  14. 14.
    Macchioni P, Catanoso MG, Pipitone N, Boiardi L, Salvarani C (2009) Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology (Oxford) 48(12):1566–1569CrossRefGoogle Scholar
  15. 15.
    De Miguel E, Roxo A, Castillo C, Peiteado D, Villalba A, Martin-Mola E (2012) The utility and sensitivity of colour Doppler ultrasound in monitoring changes in giant cell arteritis. Clin Exp Rheumatol 30(1 Suppl 70):S34–S38PubMedGoogle Scholar
  16. 16.
    Schmidt WA (2013) Polymyalgia rheumatica. Z Rheumatol 72(1):59–65CrossRefPubMedGoogle Scholar
  17. 17.
    Dasgupta B, Dolan AL, Panayi GS, Fernandes L (1998) An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 37(2):189–195CrossRefPubMedGoogle Scholar
  18. 18.
    Kyle V, Hazleman BL (1993) The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first 2 months of treatment. Ann Rheum Dis 52(12):847–850PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X (2009) Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 169(20):1839–1850CrossRefPubMedGoogle Scholar
  20. 20.
    Maradit Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32(1):65–73Google Scholar
  21. 21.
    Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT (2010) Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford) 49:716–722CrossRefGoogle Scholar
  22. 22.
    Myklebust G, Gran JT (2001) Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective 2-year study in 273 patients. Scand J Rheumatol 30:260–267CrossRefPubMedGoogle Scholar
  23. 23.
    Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Use of physician services in a population-based cohort of patients with polymyalgia rheumatica over the course of their disease. Arthr Care Res 53(3):395–403CrossRefGoogle Scholar
  24. 24.
    Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Direct medical costs of polymyalgia rheumatica. Arthritis Rheum 53(4):578–584CrossRefPubMedGoogle Scholar
  25. 25.
    Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141(7):493–500CrossRefPubMedGoogle Scholar
  26. 26.
    Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E (1996) Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 23(4):624–628PubMedGoogle Scholar
  27. 27.
    van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55(4):218–223PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG (1997) Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40(10):1873–1878CrossRefPubMedGoogle Scholar
  29. 29.
    Cleuziou C, Binard A, De Bandt M, Berthelot JM, Saraux A (2012) Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. J Rheumatol 39(2):310–313CrossRefPubMedGoogle Scholar
  30. 30.
    Macchioni P, Boiardi L, Catanoso M, Pazzola G, Salvarani C (2014) Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis 73(6):1190–1193CrossRefPubMedGoogle Scholar
  31. 31.
    Mackie SL, Arat S, da Silva J, Duarte C, Halliday S, Hughes R et al (2014) Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR. J Rheumatol 41(4):819–823CrossRefPubMedGoogle Scholar
  32. 32.
    Leeb BF, Rintelen B, Sautner J, Fassl C, Bird HA (2007) The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum 57(5):810–815CrossRefPubMedGoogle Scholar
  33. 33.
    Inflammatory Joint Disease Working Group of the French Society for Rheumatology, Binard A, de Bandt M, Berthelot JM, Saraux A (2008) Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 59(2):263–269CrossRefGoogle Scholar
  34. 34.
    Bahlas S, Ramos-Remus C, Davis P (2000) Utilisation and costs of investigations, and accuracy of diagnosis of polymyalgia rheumatica by family physicians. Clin Exp Rheumatol 19:278–280CrossRefGoogle Scholar
  35. 35.
    Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS et al (2011) Definition of remission and relapse in polymyalgia rheumatica—data from a literature search compared to a Delphi based expert consensus. Ann Rheum Dis 70(3):447–453PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Kalke S, Mukerjee D, Dasgupta B (2000) A study of the health assessment questionnaire to evaluate functional status in polymyalgia rheumatica. Rheumatology (Oxford) 39(8):883–885CrossRefGoogle Scholar
  37. 37.
    Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK (2001) Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 40(11):1238–1242CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Internal MedicineMedical University of InnsbruckInnsbruckAustria
  2. 2.Division of Rheumatology and ImmunologyMedical University of GrazGrazAustria
  3. 3.Department of RheumatologySouthend University HospitalWestcliff-on-SeaUK
  4. 4.Division of Rheumatology, Department of Health Sciences ResearchMayo Clinic College of MedicineRochesterUSA

Personalised recommendations